Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 5/2011

01-10-2011 | Original Paper

Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients

Authors: C. Sabariego, M. Brach, P. Herschbach, P. Berg, G. Stucki

Published in: The European Journal of Health Economics | Issue 5/2011

Login to get access

Abstract

Anxiety and fear are often associated with chronic conditions such as cancer. This paper targets the cost-effectiveness analysis of a cognitive-behavioral group therapy (CBT) in comparison to a client-centered, supportive-experiential group therapy (SET) in cancer patients with dysfunctional fear of progression. An incremental cost-effectiveness analysis was performed using data from a randomized controlled trial among cancer patients receiving inpatient rehabilitation. The means, 95% confidence intervals [95% CI], incremental cost-effectiveness graphic and acceptability curve were obtained from 1,000 bootstrap replications. A total of 174 patients were included in the economic evaluation. The estimated means [95% CI] of direct costs and reduction of fear of progression were €9,045.03 [6,359.07; 12,091.87] and 1.41 [0.93; 1.92] for patients in the SET and €6,682.78 [4,998.09; 8,440.95] and 1.44 [1.02; 1.09] for patients in the CBT. The incremental cost-effectiveness ratio [95% CI] amounts to minus €78,741.66 [−154,987.20; 110,486.32] for an additional unit of effect. Given the acceptability curve, there is a 92.4% chance that the CBT, compared with the SET, is cost-effective without the need of additional costs to payers. Our main result is the superior cost-effectiveness of the cognitive-behavioral intervention program in comparison to the non-directive encounter group for our sample of cancer patients with high levels of anxiety.
Literature
1.
Hoffman, D.L., Dukes, E.M., Wittchen, H.U.: Human and economic burden of generalized anxiety disorder. Depress Anxiety, 1091–4269 (2006)
2.
Andlin-Sobocki, P., Wittchen, H.U.: Cost of anxiety disorders in Europe. Eur. J. Neurol. 12(Suppl 1), 39–44 (2005)PubMedCrossRef
3.
Wittchen, H.U.: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16, 162–171 (2002)PubMedCrossRef
4.
Herschbach, P., Berg, P., Dankert, A., Duran, G., Engst-Hastreiter, U., Waadt, S., Keller, M., Ukat, R., Henrich, G.: Fear of progression in chronic diseases: psychometric properties of the fear of progression questionnaire. J. Psychsom. Res. 58, 505–511 (2005)CrossRef
5.
Sheard, T., Maguire, P.: The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br. J. Cancer 80, 1770–1780 (1999)PubMedCrossRef
6.
Meyer, T.J., Mark, M.M.: Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol. 14, 101–108 (1995)PubMedCrossRef
7.
Newell, S.A., Sanson-Fisher, R.W., Savolainen, N.J.: Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J. Natl Cancer Inst. 94, 558–584 (2002)PubMed
8.
Owen, J.E., Klapow, J.C., Hicken, B., Tucker, D.C.: Psychosocial interventions for cancer: review and analysis using a three-tiered outcomes model. Psychooncology 10, 218–230 (2001)PubMedCrossRef
9.
Herschbach, P., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G., Book, K., Dinkel, A.: Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother. Psychosom. 79, 31–38 (2010)PubMedCrossRef
10.
Herschbach, P., Book, K., Dinkel, A., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G.: Evaluation of two group therapies to reduce fear of progression in cancer patients. Support. Care Cancer 18, 471–479 (2010)PubMedCrossRef
11.
Rosenberg, H.J., Rosenberg, S.D., Ernstoff, M.S., Wolford, G.L., Amdur, R.J., Elshamy, M.R., Bauer-Wu, S.M., Ahles, T.A., Pennebaker, J.W.: Expressive disclosure and health outcomes in a prostate cancer population. Int. J. Psychiatry Med. 32, 37–53 (2002)PubMedCrossRef
12.
Simpson, J.S., Carlson, L.E., Trew, M.E.: Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 9, 19–26 (2001)PubMedCrossRef
13.
Mehnert, A., Herschbach, P., Berg, P., Henrich, G., Koch, U.: Fear of progression in breast cancer patients—validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF). Z. Psychosom. Med. Psychother. 52, 274–288 (2006)PubMed
14.
Herschbach, P., Duran, G., Engst-Rastreiter, U., Waadt, S., Berg, P.: Gruppentherapetische Behandlung von Progredienzangst bei Krebspatienten. Verhaltenstherapie Verhaltensmedizin 27, 298–309 (2006)
15.
Hessel, F., Wittman, M., Petro, W., Wasem, J.: Methoden zur Kostenerfassungim Rahmen der ökonomischen Evaluation einer Rehabilitations-maßnahme bei chronischen Atemwegserkrankungen. Pneumologie 54, 289–295 (2002)CrossRef
16.
Rote-Liste: Rote Liste Service GmbH. In: ECV Verlag, Frankfurt (2004)
17.
AOK: Vergütungsliste für Orthopädische Hilfsmittel der Primärkassen in Bayern (2004)
18.
Krauth, C., Hessel, F., Hansmeier, T., Wasem, J., Seitz, R., Schweikert, B.: Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67, 736–746 (2005)PubMedCrossRef
19.
Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., Sullivan, M.: Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessment. J. Clin. Epidemiol. 51, 1171–1178 (1998)PubMedCrossRef
20.
Barber, J.A., Thompson, S.G.: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat. Med. 19, 3219–3236 (2000)PubMedCrossRef
21.
Carpenter, J., Bithell, J.: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat. Med. 19, 1141–1164 (2000)PubMedCrossRef
22.
Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford Medical Publications, New York (1997)
23.
Briggs, A.H.: Statistical approaches to handling uncertainty in health economic evaluation. Eur. J. Gastroenterol. Hepatol. 16, 551–561 (2004)PubMedCrossRef
24.
Chiles, J.A., Lambert, M.J., Michael, J., Hatch Arlin, L.: The impact of psychological interventions on medical cost offset: a meta-analytic review. Clin. Psychol. Sci. Prax. 6, 204–220 (1999)CrossRef
25.
Knapp, M., Thorgrimsen, L., Patel, A., Spector, A., Hallam, A., Woods, B., Orrell, M.: Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br. J. Psychiatry 188, 574–580 (2006)PubMedCrossRef
26.
27.
Briggs, A., Fenn, P.: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7, 723–740 (1998)PubMedCrossRef
28.
Fenwick, E., O’Brien, B.J., Briggs, A.: Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 13, 405–415 (2004)PubMedCrossRef
29.
Heuzenroeder, L., Donnelly, M., Haby, M.M., Mihalopoulos, C., Rossell, R., Carter, R., Andrews, G., Vos, T.: Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. N. Z. J. Psychiatry 38, 602–612 (2004)PubMedCrossRef
30.
Chuang, L.H., Kind, P.: Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics 27, 491–505 (2009)PubMedCrossRef
Metadata
Title
Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients
Authors
C. Sabariego
M. Brach
P. Herschbach
P. Berg
G. Stucki
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 5/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0266-y

Other articles of this Issue 5/2011

The European Journal of Health Economics 5/2011 Go to the issue

Original paper

Atrial fibrillation: the cost of illness in Sweden

Original Paper

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor

Original Paper

Ageing and health care expenditure in EU-15

Original Paper

Cost of low back pain in Switzerland in 2005

Original Paper

Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals

Original Paper

Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare